TYK Medicines (HKSE:02410) Debt-to-Equity : -0.12 (As of Jun. 2024)

View and export this data going back to 2024. Start your Free Trial

What is TYK Medicines Debt-to-Equity?

TYK Medicines's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$111.54 Mil. TYK Medicines's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$18.41 Mil. TYK Medicines's Total Stockholders Equity for the quarter that ended in Jun. 2024 was HK$-1,126.60 Mil. TYK Medicines's debt to equity for the quarter that ended in Jun. 2024 was -0.12.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for TYK Medicines's Debt-to-Equity or its related term are showing as below:

HKSE:02410' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.13 Med: -0.11 Max: -0.05
Current: -0.12

During the past 2 years, the highest Debt-to-Equity Ratio of TYK Medicines was -0.05. The lowest was -0.13. And the median was -0.11.

HKSE:02410's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs HKSE:02410: -0.12

TYK Medicines Debt-to-Equity Historical Data

The historical data trend for TYK Medicines's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TYK Medicines Debt-to-Equity Chart

TYK Medicines Annual Data

Trend

Dec22

Dec23

Debt-to-Equity

-0.11

-0.05

TYK Medicines Quarterly Data
	Dec22	Mar23	Jun23	Dec23	Mar24	Jun24
Debt-to-Equity	Get a 7-Day Free Trial			N/A	N/A	-0.05	-0.13	-0.12

Competitive Comparison of TYK Medicines's Debt-to-Equity

For the Biotechnology subindustry, TYK Medicines's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TYK Medicines's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TYK Medicines's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where TYK Medicines's Debt-to-Equity falls into.

TYK Medicines Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

TYK Medicines's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(24.31	+	21.332)	/	-967.426
	=	-0.05

TYK Medicines's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(111.544	+	18.414)	/	-1126.601
	=	-0.12

TYK Medicines (HKSE:02410) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

TYK Medicines Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of TYK Medicines's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

TYK Medicines Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TYK Medicines Inc (HKSE:02410) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1278 Mingzhu Road, Room 1403-2, Floor 14, Tower A, Changxing World Trade Building, Zhejiang Province, Changxing Economic Development Zone, Huzhou, CHN

Website

http://www.tykmedicines.com

TYK Medicines Inc is a drug discovery research and development centre. The company and its subsidiaries are principally engaged in the research, development and commercialization of pharmaceutical products.

Executives

Nan Jing Yi Da Tou Zi Guan Li You Xian Gong Si
Nan Jing Yi Da Zi Ben Guan Li Qi Ye You Xian He Huo
Jiang Su Yi Da Gu Quan Tou Zi Ji Jin Guan Li You Xian Gong Si
Wu Yusheng	2201 Interest of corporation controlled by you
Zhu Julia Ming	2202 Interest of your spouse
Zheng Zhou Tai Ji Hong Nuo Yi Yao Gu Fen You Xian Gong Si	2101 Beneficial owner
Zhang Xing Li Yuan Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2101 Beneficial owner
He Chao	2201 Interest of corporation controlled by you
Bei Jing Hou Ji Jing Qiao Chuang Ye Tou Zi You Xian Gong Si	2201 Interest of corporation controlled by you
Bei Jing Rong Chen Hou Ji Tou Zi Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Zhang Xing Xing Zhang Chan Ye Tou Zi He Huo Qi Ye You Xian He Huo	2101 Beneficial owner

TYK Medicines Headlines

No Headlines